Skip to content

Study · Animal study (in vivo) · rat · 1998

6 results

Central infusion of melanocortin agonist MTII in rats: assessment of c-Fos expression and taste aversion.

Thiele TE, van Dijk G, Yagaloff KA, Fisher SL, Schwartz M, Burn P, Seeley RJ

The American journal of physiology1 Jan 1998Cited by 128 (Europe PMC)

PMID9458925 (opens in a new tab)DOI10.1152/ajpregu.1998.274.1.r248 (opens in a new tab)PepBankPUB-09458925
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Long-Evans rats, third-ventricle MTII at 1.0 nmol reduced 48-h food intake.

    In plain wordsIn rats, MTII given into the brain at 1.0 nmol reduced food intake over 48 hours.

    Peptide
    Melanotan II
    Outcome
    Decrease48-h food intake
    Study

    ratn: not reported in source

    Long-Evans rat
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1.0 nmol · third ventricle infusionAs given in this study (rat).

    Measurements

    dose
    1 nmol
    48-h food intake

    Source sentences

    Summary
    MTII reduced 48-h food intake (1.0 nmol dose), reduced body weight at 24 and 48 h (0.1 and 1.0 nmol doses, respectively), and induced c-Fos expression in the paraventricular nucleus of the hypothalamus and the central nucleus of the amygdala.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Long-Evans rats, third-ventricle MTII at 0.1 nmol reduced body weight at 24 h.

    In plain wordsIn rats, MTII given into the brain at 0.1 nmol lowered body weight at 24 hours.

    Peptide
    Melanotan II
    Outcome
    DecreaseBody weight at 24 h
    Study

    ratn: not reported in source

    Long-Evans rat
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.1 nmol · third ventricle infusionAs given in this study (rat).

    Measurements

    dose
    0.1 nmol
    body weight at 24 h

    Source sentences

    Summary
    reduced body weight at 24 and 48 h (0.1 and 1.0 nmol doses, respectively), and induced c-Fos expression in the paraventricular nucleus of the hypothalamus and the central nucleus of the amygdala.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Long-Evans rats, third-ventricle MTII at 1.0 nmol reduced body weight at 48 h.

    In plain wordsIn rats, MTII given into the brain at 1.0 nmol lowered body weight at 48 hours.

    Peptide
    Melanotan II
    Outcome
    DecreaseBody weight at 48 h
    Study

    ratn: not reported in source

    Long-Evans rat
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.0 nmol · third ventricle infusionAs given in this study (rat).

    Measurements

    dose
    1 nmol
    body weight at 48 h

    Source sentences

    Summary
    reduced body weight at 24 and 48 h (0.1 and 1.0 nmol doses, respectively), and induced c-Fos expression in the paraventricular nucleus of the hypothalamus and the central nucleus of the amygdala.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In Long-Evans rats, third-ventricle MTII induced c-Fos expression in the paraventricular nucleus of the hypothalamus.

    In plain wordsIn rats, MTII given into the brain increased a marker of nerve cell activity in a hypothalamus area.

    Peptide
    Melanotan II
    Outcome
    Increasec-Fos expression in the paraventricular nucleus
    Study

    ratn: not reported in source

    Long-Evans rat
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · third ventricle infusionAs given in this study (rat).

    Source sentences

    Summary
    induced c-Fos expression in the paraventricular nucleus of the hypothalamus and the central nucleus of the amygdala.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In Long-Evans rats, third-ventricle MTII induced c-Fos expression in the central nucleus of the amygdala.

    In plain wordsIn rats, MTII given into the brain increased a marker of nerve cell activity in a part of the amygdala.

    Peptide
    Melanotan II
    Outcome
    Increasec-Fos expression in the central nucleus of the amygdala
    Study

    ratn: not reported in source

    Long-Evans rat
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · third ventricle infusionAs given in this study (rat).

    Source sentences

    Summary
    induced c-Fos expression in the paraventricular nucleus of the hypothalamus and the central nucleus of the amygdala.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In Long-Evans rats, third-ventricle MTII produced conditioned taste aversions, unlike leptin.

    In plain wordsIn rats, MTII given into the brain caused a learned dislike of taste, which leptin did not.

    Peptide
    Melanotan II
    Outcome
    IncreaseConditioned taste aversion
    Study

    ratn: not reported in source

    Long-Evans rat
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · third ventricle infusionAs given in this study (rat).

    Source sentences

    Summary
    In contrast to leptin, MTII was found to produce conditioned taste aversions.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.